Published in J Clin Microbiol on July 01, 2004
Evaluation of rapid screening and pre-emptive contact isolation for detecting and controlling methicillin-resistant Staphylococcus aureus in critical care: an interventional cohort study. Crit Care (2006) 1.86
Application of molecular techniques to the study of hospital infection. Clin Microbiol Rev (2006) 1.57
Antibiotics in pandemic flu. BMJ (2006) 1.00
Rapid molecular detection of methicillin-resistant Staphylococcus aureus: a cost-effective tool for infection control in critical care? Crit Care (2006) 0.86
Sensitivity and specificity of a rapid rRNA gene probe assay for simultaneous identification of Staphylococcus aureus and detection of mecA. J Clin Microbiol (2005) 0.78
Staphylococcus aureus Colonization and Nosocomial Infections: Implications for Prevention. Curr Infect Dis Rep (2004) 0.78
Multiplex PCR-ligation detection reaction assay for simultaneous detection of drug resistance and toxin genes from Staphylococcus aureus, Enterococcus faecalis, and Enterococcus faecium. J Clin Microbiol (2009) 0.78
Detection of Vancomycin Resistant Enterococci from Rectal Swab Samples by Becton-Dickinson GeneOhm VanR assay and Culture at ICU of a Tertiary Care Center in Turkey. Pak J Med Sci (2013) 0.78
Silver Nanoparticles: Biosynthesis Using an ATCC Reference Strain of Pseudomonas aeruginosa and Activity as Broad Spectrum Clinical Antibacterial Agents. Int J Biomater (2016) 0.75
Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR. J Clin Microbiol (1995) 12.98
Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. Infection Control Programme. Lancet (2000) 11.65
Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis (2002) 11.30
SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol (2003) 10.16
Staphylococcus aureus resistant to vancomycin--United States, 2002. MMWR Morb Mortal Wkly Rep (2002) 7.34
Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications. Clin Microbiol Rev (1997) 6.98
Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother (1993) 6.28
Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett (1992) 6.12
New real-time PCR assay for rapid detection of methicillin-resistant Staphylococcus aureus directly from specimens containing a mixture of staphylococci. J Clin Microbiol (2004) 6.06
Safety of patients isolated for infection control. JAMA (2003) 5.90
Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med (2002) 5.39
Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med (2000) 5.08
Strategies to Prevent and Control the Emergence and Spread of Antimicrobial-Resistant Microorganisms in Hospitals. A challenge to hospital leadership. JAMA (1996) 4.80
Guideline for isolation precautions in hospitals. The Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol (1996) 4.36
Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis (2003) 4.06
Vancomycin-resistant Staphylococcus aureus--Pennsylvania, 2002. MMWR Morb Mortal Wkly Rep (2002) 3.95
Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis (1999) 3.77
Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis (1997) 3.29
Rapid detection of methicillin-resistant Staphylococcus aureus directly from sterile or nonsterile clinical samples by a new molecular assay. J Clin Microbiol (2003) 3.27
National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1992-June 2001, issued August 2001. Am J Infect Control (2001) 3.12
Development of a standardized screening method for detection of vancomycin-resistant enterococci. J Clin Microbiol (1994) 2.77
Antimicrobial resistance trends and outbreak frequency in United States hospitals. Clin Infect Dis (2003) 2.54
Detection of vancomycin-resistant enterococci in fecal samples by PCR. J Clin Microbiol (1997) 2.32
High rate of false-negative results of the rectal swab culture method in detection of gastrointestinal colonization with vancomycin-resistant enterococci. Clin Infect Dis (2001) 2.25
Public health focus: surveillance, prevention, and control of nosocomial infections. MMWR Morb Mortal Wkly Rep (1992) 2.12
Emergence of high-level resistance to glycopeptides in Enterococcus gallinarum and Enterococcus casseliflavus. Antimicrob Agents Chemother (1994) 1.89
Control of endemic vancomycin-resistant Enterococcus among inpatients at a university hospital. Clin Infect Dis (2003) 1.82
Adverse effects of contact isolation. Lancet (1999) 1.61
Enterococcal vanB resistance locus in anaerobic bacteria in human faeces. Lancet (2001) 1.60
Binding affinity for penicillin-binding protein 2a correlates with in vivo activity of beta-lactam antibiotics against methicillin-resistant Staphylococcus aureus. J Infect Dis (1990) 1.57
Rapid detection of vanA and vanB genes directly from clinical specimens and enrichment broths by real-time multiplex PCR assay. J Clin Microbiol (2003) 1.53
Comparison of the Vitek Gram-Positive Susceptibility 106 card and the MRSA-screen latex agglutination test for determining oxacillin resistance in clinical bloodstream isolates of Staphylococcus aureus. J Clin Microbiol (2001) 1.40
Economic impact of antimicrobial resistance. Emerg Infect Dis (2001) 1.27
Practices to improve antimicrobial use at 47 US hospitals: the status of the 1997 SHEA/IDSA position paper recommendations. Society for Healthcare Epidemiology of America/Infectious Diseases Society of America. Infect Control Hosp Epidemiol (2000) 1.22
Improved methods for detection of methicillin-resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis (2001) 1.15
Comparison of PCR assay to culture for surveillance detection of vancomycin-resistant enterococci. J Clin Microbiol (2003) 1.14
Real-time PCR for the rapid detection of vanA and vanB genes. Diagn Microbiol Infect Dis (2003) 1.03
Comparison of the Velogene Rapid MRSA Identification Assay, Denka MRSA-Screen Assay, and BBL Crystal MRSA ID System for rapid identification of methicillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis (2001) 0.99
Would active surveillance cultures help control healthcare-related methicillin-resistant Staphylococcus aureus infections? Infect Control Hosp Epidemiol (2002) 0.97
Direct detection of vanA and vanB genes in clinical specimens for rapid identification of vancomycin resistant enterococci (VRE) using multiplex PCR. Mol Cell Probes (1999) 0.93
Active surveillance reduces the incidence of vancomycin-resistant enterococcal bacteremia. Clin Infect Dis (2003) 0.90
The experience of infectious patients in isolation. Nurs Times (1993) 0.89
Evaluation of an isothermal signal amplification method for rapid detection of methicillin-resistant Staphylococcus aureus from patient-screening swabs. J Clin Microbiol (2003) 0.84
Implementation of strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in U.S. hospitals. Infect Control Hosp Epidemiol (2005) 0.80
Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med (2002) 5.39
Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol (2004) 4.70
Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis (2009) 4.59
Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis (2013) 4.14
Has antifungal susceptibility testing come of age? Clin Infect Dis (2002) 3.39
Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis (2004) 3.20
In Candida albicans, white-opaque switchers are homozygous for mating type. Genetics (2002) 2.96
Antimicrobial resistance trends and outbreak frequency in United States hospitals. Clin Infect Dis (2003) 2.54
Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine (2007) 2.51
Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol (2005) 2.26
Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains. Antimicrob Agents Chemother (2010) 2.03
Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene. Antimicrob Agents Chemother (2011) 2.01
Prevalence of extended spectrum beta-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998-99). Diagn Microbiol Infect Dis (2002) 1.83
Therapy and outcome of Candida glabrata versus Candida albicans bloodstream infection. Diagn Microbiol Infect Dis (2007) 1.80
Geographic distribution and antifungal susceptibility of the newly described species Candida orthopsilosis and Candida metapsilosis in comparison to the closely related species Candida parapsilosis. J Clin Microbiol (2008) 1.66
Clade-specific flucytosine resistance is due to a single nucleotide change in the FUR1 gene of Candida albicans. Antimicrob Agents Chemother (2004) 1.49
Flucytosine resistance is restricted to a single genetic clade of Candida albicans. Antimicrob Agents Chemother (2004) 1.49
Candida guilliermondii and other species of candida misidentified as Candida famata: assessment by vitek 2, DNA sequencing analysis, and matrix-assisted laser desorption ionization-time of flight mass spectrometry in two global antifungal surveillance programs. J Clin Microbiol (2012) 1.47
Homozygosity at the Candida albicans MTL locus associated with azole resistance. Microbiology (2002) 1.43
Statistical analyses of correlation between fluconazole MICs for Candida spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2). J Clin Microbiol (2006) 1.43
First description of Klebsiella pneumoniae harboring CTX-M beta-lactamases (CTX-M-14 and CTX-M-3) in Taiwan. Antimicrob Agents Chemother (2002) 1.42
Lodderomyces elongisporus masquerading as Candida parapsilosis as a cause of bloodstream infections. J Clin Microbiol (2007) 1.42
Emergence of fluconazole resistance in a Candida parapsilosis strain that caused infections in a neonatal intensive care unit. J Clin Microbiol (2005) 1.37
Tiamulin activity against fastidious and nonfastidious veterinary and human bacterial isolates: initial development of in vitro susceptibility test methods. J Clin Microbiol (2002) 1.37
Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods. Diagn Microbiol Infect Dis (2002) 1.36
Caspofungin Etest susceptibility testing of Candida species: risk of misclassification of susceptible isolates of C. glabrata and C. krusei when adopting the revised CLSI caspofungin breakpoints. Antimicrob Agents Chemother (2012) 1.31
Frequency of fks mutations among Candida glabrata isolates from a 10-year global collection of bloodstream infection isolates. Antimicrob Agents Chemother (2013) 1.29
Hepatitis C virus viremia in HIV-infected individuals with negative HCV antibody tests. J Acquir Immune Defic Syndr (2002) 1.29
Cefepime MIC as a predictor of the extended-spectrum beta-lactamase type in Klebsiella pneumoniae, Taiwan. Emerg Infect Dis (2002) 1.25
Effect of a second-generation venous catheter impregnated with chlorhexidine and silver sulfadiazine on central catheter-related infections: a randomized, controlled trial. Ann Intern Med (2005) 1.23
Outbreak of Candida rugosa candidemia: an emerging pathogen that may be refractory to amphotericin B therapy. Diagn Microbiol Infect Dis (2003) 1.21
Identification of Candida nivariensis and Candida bracarensis in a large global collection of Candida glabrata isolates: comparison to the literature. J Clin Microbiol (2009) 1.21
Analysis of ALS5 and ALS6 allelic variability in a geographically diverse collection of Candida albicans isolates. Fungal Genet Biol (2007) 1.16
Rapid detection of antibiotic-resistant organism carriage for infection prevention. Clin Infect Dis (2013) 1.16
Dispersal of Staphylococcus aureus into the air associated with a rhinovirus infection. Infect Control Hosp Epidemiol (2005) 1.15
Decreasing prevalence of beta-lactamase production among respiratory tract isolates of Haemophilus influenzae in the United States. Antimicrob Agents Chemother (2005) 1.15
Rationale for reading fluconazole MICs at 24 hours rather than 48 hours when testing Candida spp. by the CLSI M27-A2 standard method. Antimicrob Agents Chemother (2008) 1.11
Improving typeability of multiple bacterial species using pulsed-field gel electrophoresis and thiourea. Diagn Microbiol Infect Dis (2003) 1.11
Identification and Susceptibility Profile of Candida fermentati from a worldwide collection of Candida guilliermondii clinical isolates. J Clin Microbiol (2008) 1.10
Evidence for recombination in Candida glabrata. Fungal Genet Biol (2005) 1.10
Molecular epidemiology of macrolide resistance in neonatal bloodstream isolates of group B streptococci. J Clin Microbiol (2003) 1.09
A prospective study of outcomes, healthcare resource utilization, and costs associated with postoperative nosocomial infections. Infect Control Hosp Epidemiol (2006) 1.09
Are United States hospitals following national guidelines for the analysis and presentation of cumulative antimicrobial susceptibility data? Diagn Microbiol Infect Dis (2004) 1.09
Evaluation of three molecular typing techniques for nonfermentative Gram-negative bacilli. Infect Control Hosp Epidemiol (2004) 1.08
Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn Microbiol Infect Dis (2002) 1.05
Change in colony morphology of Candida lusitaniae in association with development of amphotericin B resistance. Antimicrob Agents Chemother (2002) 1.05
Modification of dienes mutual inhibition test for epidemiological characterization of Pseudomonas aeruginosa isolates. J Clin Microbiol (2002) 1.05
Presentation of the PATH Alliance registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections. Diagn Microbiol Infect Dis (2007) 1.02
Emergence of two Klebsiella pneumoniae isolates harboring plasmid-mediated CTX-M-15 beta-lactamase in Taiwan. Antimicrob Agents Chemother (2004) 0.99
Donor-to-host transmission of Candida albicans after corneal transplantation. Am J Ophthalmol (2002) 0.98
Screening of a large global Aspergillus fumigatus species complex collection by using a species-specific microsphere-based Luminex assay. J Clin Microbiol (2009) 0.98
Nosocomial candidemia: an ounce of prevention is better than a pound of cure. Infect Control Hosp Epidemiol (2004) 0.98
Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis. Diagn Microbiol Infect Dis (2006) 0.97
Preoperative risk factors for nasal carriage of Staphylococcus aureus. Infect Control Hosp Epidemiol (2004) 0.97
Molecular phylogenetic analysis of a geographically and temporally matched set of Candida albicans isolates from humans and nonmigratory wildlife in central Illinois. Eukaryot Cell (2008) 0.97
Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000). Diagn Microbiol Infect Dis (2002) 0.96
Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection. Diagn Microbiol Infect Dis (2009) 0.95
Epidemiology of methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus in a rural state. Infect Control Hosp Epidemiol (2006) 0.95
Candida glabrata mutants demonstrating paradoxical reduced caspofungin susceptibility but increased micafungin susceptibility. Antimicrob Agents Chemother (2011) 0.95
A global evaluation of voriconazole activity tested against recent clinical isolates of Candida spp. Diagn Microbiol Infect Dis (2008) 0.95
Characterization of biofilms formed by Candida parapsilosis, C. metapsilosis, and C. orthopsilosis. Int J Med Microbiol (2009) 0.95
Clade-related amphotericin B resistance among South African Candida albicans isolates. Diagn Microbiol Infect Dis (2005) 0.94
BMS284756 (formerly T-3811, a des-fluoroquinolone) potency and spectrum tested against over 10,000 bacterial bloodstream infection isolates from the SENTRY antimicrobial surveillance programme (2000). J Antimicrob Chemother (2002) 0.94
Confirmation of extended-spectrum beta-lactamase-producing Serratia marcescens: preliminary report from Taiwan. Diagn Microbiol Infect Dis (2003) 0.93
Multilaboratory testing of two-drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis. Antimicrob Agents Chemother (2011) 0.93
Multilaboratory testing of antifungal combinations against a quality control isolate of Candida krusei. Antimicrob Agents Chemother (2008) 0.92
Collaborative study of the NCCLS and flow cytometry methods for antifungal susceptibility testing of Candida albicans. J Clin Microbiol (2004) 0.91
Preventing the airborne spread of Staphylococcus aureus by persons with the common cold: effect of surgical scrubs, gowns, and masks. Infect Control Hosp Epidemiol (2007) 0.90
Evaluation of Etest and disk diffusion methods compared with broth microdilution antifungal susceptibility testing of clinical isolates of Candida spp. against posaconazole. J Clin Microbiol (2007) 0.90
Activity of amphotericin B, anidulafungin, caspofungin, micafungin, posaconazole, and voriconazole against Candida albicans with decreased susceptibility to fluconazole from APECED patients on long-term azole treatment of chronic mucocutaneous candidiasis. Diagn Microbiol Infect Dis (2008) 0.89
Uncoupling of oxidative phosphorylation enables Candida albicans to resist killing by phagocytes and persist in tissue. Cell Microbiol (2006) 0.89
Evaluation of disk diffusion and Etest compared to broth microdilution for antifungal susceptibility testing of posaconazole against clinical isolates of filamentous fungi. J Clin Microbiol (2007) 0.87
Ciprofloxacin as broad-spectrum empiric therapy--are fluoroquinolones still viable monotherapeutic agents compared with beta-lactams: data from the MYSTIC Program (US)? Diagn Microbiol Infect Dis (2002) 0.86
Multicenter comparison of the Vitek 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing caspofungin, micafungin, and posaconazole against Candida spp. J Clin Microbiol (2011) 0.84
Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods. Antimicrob Agents Chemother (2011) 0.83
The yeast connection: is Candida linked to breastfeeding associated pain? Am J Obstet Gynecol (2007) 0.83
Fixed-ratio combination testing of an echinocandin, anidulafungin, and an azole, voriconazole, against 1,467 Candida species isolates. Antimicrob Agents Chemother (2010) 0.81
Comparison of an automated ribotyping system to restriction endonuclease analysis and pulsed-field gel electrophoresis for differentiating vancomycin-resistant Enterococcus faecium isolates. J Clin Microbiol (2002) 0.81
"Gesundheit!" sneezing, common colds, allergies, and Staphylococcus aureus dispersion. J Infect Dis (2006) 0.81
Performance of fusidic acid (CEM-102) susceptibility testing reagents: broth microdilution, disk diffusion, and Etest methods as applied to Staphylococcus aureus. J Clin Microbiol (2010) 0.80
[Nocardiosis in immunocompromised host presenting as cellulitis]. Laeknabladid (2010) 0.79
An outbreak of Staphylococcus aureus in a pediatric cardiothoracic surgery unit. Infect Control Hosp Epidemiol (2002) 0.79
Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values. Mycopathologia (2014) 0.78
Oral beta-lactams in the treatment of acute bacterial rhinosinusitis. Diagn Microbiol Infect Dis (2007) 0.78
In vitro assessment of gatifloxacin spectrum and potency tested against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from the Asia-Western Pacific component of the SENTRY antimicrobial surveillance program (1998-1999). Diagn Microbiol Infect Dis (2002) 0.78
Airborne dispersal of Staphylococcus aureus associated with symptomatic rhinitis allergica. Ann Intern Med (2003) 0.77
Invasive mycoses: evolving challenges and opportunities in antifungal therapy (multimedia activity). Am J Med (2011) 0.76
Presumptive identification of Candida kefyr on levine formulation of eosin methylene blue agar. J Clin Microbiol (2002) 0.75
Ronald N. Jones, MD, editor-in-chief, diagnostic microbiology and infectious disease, 1989-2013. Diagn Microbiol Infect Dis (2013) 0.75
Oral beta-lactams in the treatment of acute otitis media. Diagn Microbiol Infect Dis (2007) 0.75
Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15). J Antimicrob Chemother (2017) 0.75
Candida albicans isolates from APECED patients show decreased susceptibility to miconazole. Int J Antimicrob Agents (2009) 0.75
A case of recurrent episodes of Candida parapsilosis fungemia. Mycopathologia (2006) 0.75
Airborne dispersal as a novel transmission route of coagulase-negative staphylococci: interaction between coagulase-negative staphylococci and rhinovirus infection. Infect Control Hosp Epidemiol (2004) 0.75
Genotypic characterization of carbapenem-nonsusceptible Acinetobacter spp. isolated in Latin America. Microb Drug Resist (2004) 0.75